Skip to main content

Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · IEX Real-Time Price · USD
176.92 -3.36 (-1.86%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap21.16B
Revenue (ttm)749.31M
Net Income (ttm)-837.90M
Shares Out119.60M
EPS (ttm)-7.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume692,578
Open181.23
Previous Close180.28
Day's Range176.47 - 183.95
52-Week Range123.47 - 212.00
Beta0.90
AnalystsBuy
Price Target207.10 (+17.1%)
Earnings DateOct 28, 2021

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatme...

IndustryBiotechnology
IPO DateMay 28, 2004
CEOJohn Maraganore
Employees1,453
Stock ExchangeNASDAQ
Ticker SymbolALNY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is 207.10, which is an increase of 17.06% from the latest price.

Price Target
$207.10
(17.06% upside)
Analyst Consensus: Buy

News

Alnylam Ranks #1 in Boston Globe's Top Places to Work List for 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has ranked first in Boston Globe's 2021 Top Places to Work in t...

6 days ago - Business Wire

Alnylam to Webcast Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following co...

2 weeks ago - Business Wire

Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock

RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M&A optionality is "nice" to have, analyst Luca Iss...

2 weeks ago - Benzinga

Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcas...

2 weeks ago - Business Wire

Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive interim results from the ongoing Phase 1 study of zilebes...

3 weeks ago - Business Wire

Alnylam to Webcast Virtual R&D Day

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Inv...

3 weeks ago - Business Wire

Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Contr...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-2, a global Phase 2 study to evaluate the eff...

1 month ago - Business Wire

Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hype...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive results from the 6-month primary analysis of the ILLUMINA...

1 month ago - Business Wire

The Vanguard Health Care Fund's Top 5 Trades of the 3rd Quarter

The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.

Other symbols:ABTBIIBPFE
1 month ago - GuruFocus

Alnylam Named a Science Magazine Top Employer for Third Consecutive Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has ranked third in Science's 2021 Top Employers Survey. T...

1 month ago - Business Wire

Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates

Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021.

1 month ago - Zacks Investment Research

Why Alnylam Pharmaceuticals Stock Is Tanking This Week

The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.

1 month ago - The Motley Fool

Why Alnylam Pharmaceuticals Is Crashing Today

The company's earnings fell short of expectations and its CEO is leaving.

1 month ago - The Motley Fool

Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of -13.91% and -15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended Sept...

1 month ago - Business Wire

Alnylam Announces Planned CEO Leadership Transition

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition of John Maraganore, Ph.D., to Yvonne Gr...

1 month ago - Business Wire

Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Am...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational ...

1 month ago - Business Wire

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

3 Top Breakout Stocks to Buy Right Now

They're near record highs and their momentum could continue.

Other symbols:CELHGOOGGOOGL
1 month ago - The Motley Fool

Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending...

1 month ago - Business Wire

3 Growth Stocks Near 52-Week Highs to Buy Anyway

These top performers have what it takes to keep providing outsized gains for patient investors.

Other symbols:PANWXENE
1 month ago - The Motley Fool

Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to U...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of Alnylam Challengers, a signature community impact pr...

1 month ago - Business Wire

Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonu...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new pre-clinical research results demonstrating continued RNAi the...

2 months ago - Business Wire

Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Vir...

2 months ago - Business Wire

Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

2 months ago - Zacks Investment Research